Gouty Arthritis (Gout) – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides data on the gouty arthritis clinical trial scenario. This report provides top-line data relating to the clinical trials on Gouty Arthritis (Gout). The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
Gouty Arthritis (Gout) clinical trial report consists of 751 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 34, 62, 107, 367, and 4 respectively. Similarly, the trials with different status compile of Completed – 484, Ongoing – 93, Planned – 98, Suspended – 6, Terminated – 13, and Withdrawn – 57. Out of 484 completed trials 267 trials have achieved end points.
What are the market dynamics of the global gouty arthritis therapeutics clinical trials sector?
The number of gouty arthritis (gout) clinical trials conducted globally, has increased by 210% for the period 2016-2020. The average number of patients enrolled was highest in the year 2017. Companies were the leading sponsor for gouty arthritis clinical trials followed by institutions and governments. As of November 2021, out of 484 completed trials, 312 trials have results and over 86% of trials reached end points. There were 93 clinical trials in progress and 484 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 76. This was due to the lack of efficacy, safety, and lack of accrual of subjects. The majority of the trials were successfully completed. There were 93 clinical trials in progress of which over 30% were in Phase II study. There were 389 clinical trials in Phase I, of which 22 clinical trials were in progress for the time period 1995-2021.
What are the top regions and countries in the global gouty arthritis therapeutics clinical trials sector?
In total there were 751 clinical trials conducted on gouty arthritis (gout), as of November 2021, of these 361 clinical trials were in Asia-Pacific. More than 45% of the clinical trials were conducted in Asia-Pacific.
Asia-Pacific: As of November 2021, in the Asia-Pacific region, China has the highest number of gouty arthritis clinical trials followed by Japan, India, Australia, and Thailand.
Europe: Among the European countries, Russia has the highest number of gouty arthritis clinical trials, as of November 2021, followed by the UK, Germany, Poland, and Switzerland.
North America: In the country-wise analysis, the US has the highest number of gouty arthritis clinical trials, as of November 2021 followed by Canada and Mexico.
Middle East & Africa: South Africa has the highest number of gouty arthritis clinical trials, as of November 2021 followed by Israel, Iran, and Jordan.
Central and South America: Argentina has the highest number of gouty arthritis clinical trials, in the region followed by Colombia, Guatemala, Brazil, and Costa Rica.
G7 countries: Among the G7 (The US, the UK, Germany, France, Italy, Canada, and Japan) countries, The US has the highest proportion of gouty arthritis to musculoskeletal disorders clinical trials as of November 2021. In total there were 307 clinical trials conducted on Gouty Arthritis (Gout), as of November 2021 in G7 Countries, of these 189 clinical trials were in the US. There were 20 clinical trials in progress and 216 trials are completed. The trials that are terminated/suspended or withdrawn accounted to 13. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, China has the highest proportion of gouty arthritis to musculoskeletal disorders clinical trials as of November 2021. In total there were 301 clinical trials conducted on Gouty Arthritis (Gout), as of November 2021 in E7 Countries, of these 190 clinical trials were in China. There were 55 clinical trials in progress and 130 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 30.
Global gouty arthritis therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global gouty arthritis therapeutics clinical trials sector?
As of November 2021, AstraZeneca Plc has conducted the highest number of gouty arthritis (gout) clinical trials followed by Takeda Pharmaceutical Co Ltd. Other major players include Fuji Yakuhin Co Ltd, Sun Pharmaceutical Industries Ltd, Novartis AG, Jiangsu Hengrui Medicine Co Ltd, PRACS Institute, Ltd. (Inactive), Teijin Ltd, CymaBay Therapeutics Inc, and Suzuken Co Ltd.
Global gouty arthritis therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | China, The US, Russia, Japan, India, Australia, Canada, Thailand, New Zealand, and the UK |
Key companies | AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, Fuji Yakuhin Co Ltd, Sun Pharmaceutical Industries Ltd, Novartis AG, Jiangsu Hengrui Medicine Co Ltd, PRACS Institute, Ltd. (Inactive), Teijin Ltd, CymaBay Therapeutics Inc, and Suzuken Co Ltd. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for un-accomplishment.
- The report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrolment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Takeda Pharmaceutical Co Ltd
Fuji Yakuhin Co Ltd
Sun Pharmaceutical Industries Ltd
Novartis AG
Jiangsu Hengrui Medicine Co Ltd
PRACS Institute, Ltd. (Inactive)
Teijin Ltd
CymaBay Therapeutics Inc
Suzuken Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global gouty arthritis therapeutics clinical trials sector?
The key countries in the global gouty arthritis therapeutics clinical trials sector are China, the US, Russia, Japan, India, Australia, Canada, Thailand, New Zealand, and the UK.
-
Which are the key companies in the global gouty arthritis therapeutics clinical trials sector?
The key companies in the global gouty arthritis therapeutics clinical trials sector are AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, Fuji Yakuhin Co Ltd, Sun Pharmaceutical Industries Ltd, Novartis AG, Jiangsu Hengrui Medicine Co Ltd, PRACS Institute, Ltd. (Inactive), Teijin Ltd, CymaBay Therapeutics Inc, and Suzuken Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.